ArrowMark Colorado Holdings LLC Acquires 34,689 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

ArrowMark Colorado Holdings LLC lifted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 917,420 shares of the biopharmaceutical company's stock after acquiring an additional 34,689 shares during the quarter. ArrowMark Colorado Holdings LLC owned approximately 1.61% of Agios Pharmaceuticals worth $30,146,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AGIO. Adage Capital Partners GP L.L.C. bought a new stake in Agios Pharmaceuticals during the 4th quarter worth about $9,957,000. CenterBook Partners LP raised its stake in shares of Agios Pharmaceuticals by 98.3% during the fourth quarter. CenterBook Partners LP now owns 305,599 shares of the biopharmaceutical company's stock worth $10,042,000 after buying an additional 151,511 shares during the last quarter. Norges Bank bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth approximately $4,768,000. Artisan Partners Limited Partnership lifted its holdings in Agios Pharmaceuticals by 27.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 499,134 shares of the biopharmaceutical company's stock valued at $16,402,000 after buying an additional 107,292 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in Agios Pharmaceuticals by 12.3% in the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after acquiring an additional 105,333 shares during the last quarter.

Agios Pharmaceuticals Trading Down 0.4 %

Shares of NASDAQ AGIO traded down $0.13 during mid-day trading on Monday, reaching $29.97. 358,855 shares of the company's stock were exchanged, compared to its average volume of 699,505. Agios Pharmaceuticals, Inc. has a twelve month low of $23.42 and a twelve month high of $62.58. The firm has a market capitalization of $1.74 billion, a price-to-earnings ratio of 2.64 and a beta of 0.83. The business has a fifty day simple moving average of $29.72 and a 200 day simple moving average of $37.65.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping the consensus estimate of ($1.80) by $0.25. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. HC Wainwright started coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price target on the stock. Scotiabank cut their target price on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday. Finally, StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $56.00.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the sale, the director now owns 149,220 shares of the company's stock, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.93% of the stock is currently owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.